Clinical trial
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR®…
NCT00268983 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00268983 |
|---|---|
| Title | Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma |
| Official title | A Multi-Center, Randomized, Phase 3 Study of Rituximab Versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin |
| Intervention type | Biological |
| Interventions | Tositumomab and Iodine I 131 Tositumomab, Rituximab |
| Enrollment | 14 |
| Start date | Oct 1, 2004 |
| Primary completion | Sep 1, 2009 |
| Completion | Jun 1, 2013 |
| First posted | Dec 23, 2005 |
| Last update posted | Jan 9, 2017 |
| Countries | France, United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: